Department of Life Science Informatics, B-IT, LIMES Program Unit Chemical Biology and Medicinal Chemistry, Rheinische Friedrich-Wilhelms-Universität, Friedrich-Hirzebruch-Allee 6, D-53115 Bonn, Germany.
Department of Life Science Informatics, B-IT, LIMES Program Unit Chemical Biology and Medicinal Chemistry, Rheinische Friedrich-Wilhelms-Universität, Friedrich-Hirzebruch-Allee 6, D-53115 Bonn, Germany.
Bioorg Med Chem. 2021 Jul 1;41:116226. doi: 10.1016/j.bmc.2021.116226. Epub 2021 May 25.
Given the increasing quest for selective kinase inhibitors, we have systematically investigated structural and structure-promiscuity relationships between promiscuous kinase inhibitors and other types with increasing potential for selective kinase inhibition. Therefore, inhibitors with different modes of action were extracted from X-ray structures of kinase complexes. For more than 18,000 promiscuous kinase inhibitors and 1253 type I/, II, and allosteric inhibitors with structurally confirmed mechanisms, analogue space was systematically charted. These inhibitors were active against a total of 426 human kinases. While nearly 80% of the promiscuous inhibitors formed related analogues series, only ~30% of other types of inhibitors were involved in such structural relationships and many of these inhibitors also had multi-kinase activity. Thus, most of the investigated type I/, II, and allosteric inhibitors with reported single-kinase activity were distinguished from promiscuous inhibitors, thus indicating potential for kinase selectivity. Structural relationships between promiscuous inhibitors and the subset of other inhibitors were organized in a matrix format including kinase activity profiles, revealing structure-promiscuity relationships for follow-up investigations.
鉴于对选择性激酶抑制剂的需求不断增加,我们系统地研究了混杂激酶抑制剂与其他类型抑制剂之间的结构和结构混杂关系,这些抑制剂具有越来越大的选择性激酶抑制潜力。因此,我们从激酶复合物的 X 射线结构中提取了具有不同作用模式的抑制剂。对于超过 18000 种混杂激酶抑制剂和 1253 种 I/II 型和别构抑制剂,我们系统地绘制了类似物空间。这些抑制剂对总共 426 种人类激酶具有活性。虽然近 80%的混杂抑制剂形成了相关的类似物系列,但只有约 30%的其他类型抑制剂参与了这种结构关系,而且这些抑制剂中的许多也具有多激酶活性。因此,大多数具有报道的单一激酶活性的研究 I/II 型和别构抑制剂与混杂抑制剂区分开来,从而表明其具有激酶选择性的潜力。混杂抑制剂与其他抑制剂子集之间的结构关系以矩阵格式组织,包括激酶活性谱,揭示了后续研究的结构混杂关系。